We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$99.1B
AUM Growth
+$7.92B
Cap. Flow
+$3.27B
Cap. Flow %
3.3%
Top 10 Hldgs %
23.39%
Holding
4,186
New
432
Increased
2,037
Reduced
1,399
Closed
199

Sector Composition

Rank Sector Weight
1 Technology 14%
2 Financials 8.86%
3 Healthcare 8.09%
4 Industrials 6.83%
5 Consumer Discretionary 6.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OMC icon
3901
CALL
Omnicom Group
OMC
$23.5B
$16K ﹤0.01%
+22,300
New +$1.54M
NAK
3902
Northern Dynasty Minerals
NAK
$953M
$15K ﹤0.01%
+23,149
New +$15.1K
NMTR
3903
DELISTED
9 Meters Biopharma
NMTR
$15K ﹤0.01%
650
EVRI
3904
CALL
DELISTED
Everi Holdings
EVRI
$14K ﹤0.01%
+30,200
New +$429K
HTGC icon
3905
CALL
Hercules Capital
HTGC
$3.14B
$14K ﹤0.01%
+46,300
New +$718K
NEPT
3906
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$14K ﹤0.01%
+8
New +$20.2K
XLE icon
3907
CALL
State Street Energy Select Sector SPDR ETF
XLE
$39.8B
$13K ﹤0.01%
45,200
+21,200
+88% +$489K
VBIV
3908
CALL
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$13K ﹤0.01%
1,313
-960
-42% -$97.3K
A icon
3909
CALL
Agilent Technologies
A
$42.3B
$12K ﹤0.01%
+10,700
New +$1.32M
FCX icon
3910
CALL
Freeport-McMoran
FCX
$95.8B
$12K ﹤0.01%
35,700
+25,600
+253% +$830K
B
3911
CALL
Barrick Mining
B
$67.8B
$12K ﹤0.01%
81,200
+32,200
+66% +$694K
NTR icon
3912
CALL
Nutrien
NTR
$32.1B
$12K ﹤0.01%
29,300
-7,400
-20% -$402K
C icon
3913
CALL
Citigroup
C
$228B
$11K ﹤0.01%
18,900
-16,800
-47% -$1.12M
KO icon
3914
CALL
Coca-Cola
KO
$373B
$11K ﹤0.01%
12,400
+1,300
+12% +$65.4K
T icon
3915
CALL
AT&T
T
$167B
$11K ﹤0.01%
94,401
+74,144
+366% +$1.64M
WFC icon
3916
CALL
Wells Fargo
WFC
$265B
$11K ﹤0.01%
+38,100
New +$1.35M
CFMS
3917
DELISTED
Conformis, Inc. Common Stock
CFMS
$11K ﹤0.01%
+444
New +$12K
SCVX.WS
3918
DELISTED
SCVX Corp.
SCVX.WS
$11K ﹤0.01%
+10,500
New +$17.6K
GSK icon
3919
CALL
GSK
GSK
$103B
$9K ﹤0.01%
13,200
SYF icon
3920
CALL
Synchrony
SYF
$25.6B
$9K ﹤0.01%
21,100
-47,100
-69% -$1.82M
FXI icon
3921
CALL
iShares China Large-Cap ETF
FXI
$4.25B
$8K ﹤0.01%
11,400
IFRX icon
3922
CALL
InflaRx
IFRX
$295M
$8K ﹤0.01%
15,000
-3,000
-17% -$15.4K
MDXG icon
3923
CALL
MiMedx Group
MDXG
$625M
$8K ﹤0.01%
+20,000
New +$193K
PSEC icon
3924
CALL
Prospect Capital
PSEC
$1.15B
$8K ﹤0.01%
+76,000
New +$525K
MJ icon
3925
CALL
Amplify Alternative Harvest ETF
MJ
$108M
$6K ﹤0.01%
+1,658
New +$438K

Similar funds

Raymond James & Associates's Q1 2021 Portfolio in Review

As of Q1 2021, Raymond James & Associates held 4,186 positions worth $99.1B, up 8.7% from $91.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates deployed $3.27B of net new capital in Q1 2021, opening 432 new positions and adding to 2,037 existing holdings. Its largest new stake was BlackRock Technology and Private Equity Term Trust: 1,676,875 shares worth $34M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Vanguard High Dividend Yield ETF, an estimated $671M trimmed.

  • Raymond James & Associates's largest Q1 2021 buy was BlackRock Technology and Private Equity Term Trust: 1,676,875 shares worth $34M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q1 2021, an estimated $1.36B increase.
  • Raymond James & Associates's biggest Q1 2021 reduction was Vanguard High Dividend Yield ETF, cutting an estimated $671M.
  • Raymond James & Associates fully exited Sensient Technologies in Q1 2021, selling an estimated $15.6M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $99.1B portfolio in Q1 2021.
  • Raymond James & Associates opened 432 new positions and closed 199 in Q1 2021.
  • Raymond James & Associates's portfolio value rose 8.7% quarter-over-quarter to $99.1B.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.